about
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersEpigenetic differences arise during the lifetime of monozygotic twinsGenome-wide association studies identify four ER negative-specific breast cancer risk lociGenome-wide association study identifies novel breast cancer susceptibility lociGenome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskBRCA2 acts as a RAD51 loader to facilitate telomere replication and cappingPathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutationsLarge-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repairPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSRare mutations in XRCC2 increase the risk of breast cancerDeep sequencing of target linkage assay-identified regions in familial breast cancer: methods, analysis pipeline and troubleshootingLarge-scale genotyping identifies 41 new loci associated with breast cancer risk.Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European DescentIdentification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer.Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies.Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies.Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation CarriersMolecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage ConsortiumParent-of-origin-specific allelic associations among 106 genomic loci for age at menarcheGenetic variation in mitotic regulatory pathway genes is associated with breast tumor gradeHaplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study.Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.Recurrence of Down's syndrome associated with microchromosome.MicroRNA related polymorphisms and breast cancer risk.Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles.Oxidative stress in susceptibility to breast cancer: study in Spanish population.Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Five polymorphisms and breast cancer risk: results from the Breast Cancer Association ConsortiumEvidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general populationIdentification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer riskInherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer.Genetic predisposition to in situ and invasive lobular carcinoma of the breast.Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study.Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy
P50
Q21144874-F3F5CF7C-AE61-4BF9-8BFE-20131B4C26E1Q24531005-3FB1CFCD-566D-4514-8287-1E8AD2EE406AQ24622610-4F9610BB-E977-414D-BAFF-6F40732B9CC7Q24645441-3F9E891F-8B8A-4973-8CA8-7D9A0A1086B5Q27008356-AE7F0B17-16C1-40B5-B6AE-680DEFC5B4E0Q28115349-C0A1CEC4-2CFC-4C50-AF9F-ECC577F4CB30Q28265304-3DA4779C-29CA-4F89-97F6-33E86E510BE5Q28267893-E8F3125C-92AD-411A-848B-2E3188E684C8Q28584533-274A296A-6FD6-43E2-A66B-F210AD072344Q28730692-C86685E8-4DDD-4C3D-8BA5-3D640D084BD8Q28748212-64894652-65C1-4244-9500-59AEC65923F2Q29416989-E031D7C3-07C9-4FD9-9AC4-5B0914047467Q30000080-064455E2-24FB-46E0-B80C-EEE6EF73953FQ30252854-9654F555-A6CE-4428-8276-A76C92B695AAQ30374367-A7D61591-08B7-4F28-90DB-D604DF23AE4AQ30660858-462BB41C-135C-41BD-B1EA-0A6C1D8F1FE1Q31043651-C906ECC7-B061-4232-946C-4068E11E8081Q33296082-85142E76-4DCE-465A-ADD6-27CB5F66E014Q33395472-60B52771-86CB-4B18-BADE-DDF7E070428EQ33614244-EC4DAC86-23FA-4BB4-BD69-D24CB3FCC6E1Q33710107-E5B9648C-0999-47AF-8214-A03D5ADA9F2CQ33894527-325ED229-8B14-4D81-B04B-1A8598F0271DQ34289136-62112EAB-B5DC-4E41-8F27-A497E450E4ECQ34378972-F963210D-4858-4CD4-BDE5-1ECEBDBDEECBQ34385784-3414AACD-772B-43F4-80B0-5DF4B6FB1745Q34394665-4CD47EF8-E91B-4288-A5F3-FF1722622A4AQ34397860-308E35C5-11EB-4896-9D00-6E1EA0EE6F60Q34497352-3B71EFDC-AC57-4D29-9E70-065557035D75Q34586198-94FB2FA4-233B-4DE7-9EFC-14CB5F9BA455Q34610274-CA2D72B3-A755-49ED-BCF2-85F39FAA4A6BQ34903062-03615296-70F6-420D-879F-D23F6C72AE17Q34963894-C1DD736E-CF3B-4AB4-836F-2F59E0875AA7Q34979715-9F3C8897-8EB5-4DA7-A1BA-6CDDB15FBB9FQ35064451-E9EDB3C1-B8DA-4EA7-BB15-EBAC58CE2F09Q35089479-17E55F99-6351-4C83-996A-0B9D046B28CEQ35102646-86032F69-2470-4399-9FCC-0BE70BC6BB62Q35104068-442373F6-6D23-4C90-97D5-48D0FD19EE9CQ35151684-5B255C69-E722-4991-9E8C-FCB4A55A68F6Q35179897-EC3A0B9A-C83F-467A-9336-33CEAFB6A1A2Q35218520-6E3EAE38-BE39-4C15-81AB-C92AD5C04E1B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Javier Benitez
@ast
Javier Benitez
@en
Javier Benitez
@es
Javier Benitez
@nl
type
label
Javier Benitez
@ast
Javier Benitez
@en
Javier Benitez
@es
Javier Benitez
@nl
prefLabel
Javier Benitez
@ast
Javier Benitez
@en
Javier Benitez
@es
Javier Benitez
@nl
P106
P21
P31
P496
0000-0002-0923-7202